Cargando…
The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin
The intrinsically disordered protein α-synuclein (aSN) is, in its fibrillated state, the main component of Lewy bodies—hallmarks of Parkinson’s disease. Additional Lewy body components include glycosaminoglycans, including heparan sulfate proteoglycans. In humans, heparan sulfate has, in an age-depe...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464290/ https://www.ncbi.nlm.nih.gov/pubmed/32824376 http://dx.doi.org/10.3390/biom10081192 |
_version_ | 1783577330573115392 |
---|---|
author | Skaanning, Line K. Santoro, Angelo Skamris, Thomas Martinsen, Jacob Hertz D’Ursi, Anna Maria Bucciarelli, Saskia Vestergaard, Bente Bugge, Katrine Langkilde, Annette Eva Kragelund, Birthe B. |
author_facet | Skaanning, Line K. Santoro, Angelo Skamris, Thomas Martinsen, Jacob Hertz D’Ursi, Anna Maria Bucciarelli, Saskia Vestergaard, Bente Bugge, Katrine Langkilde, Annette Eva Kragelund, Birthe B. |
author_sort | Skaanning, Line K. |
collection | PubMed |
description | The intrinsically disordered protein α-synuclein (aSN) is, in its fibrillated state, the main component of Lewy bodies—hallmarks of Parkinson’s disease. Additional Lewy body components include glycosaminoglycans, including heparan sulfate proteoglycans. In humans, heparan sulfate has, in an age-dependent manner, shown increased levels of sulfation. Heparin, a highly sulfated glycosaminoglycan, is a relevant mimic for mature heparan sulfate and has been shown to influence aSN fibrillation. Here, we decompose the underlying properties of the interaction between heparin and aSN and the effect of heparin on fibrillation. Via the isolation of the first 61 residues of aSN, which lacked intrinsic fibrillation propensity, fibrillation could be induced by heparin, and access to the initial steps in fibrillation was possible. Here, structural changes with shifts from disorder via type I β-turns to β-sheets were revealed, correlating with an increase in the aSN(1–61)/heparin molar ratio. Fluorescence microscopy revealed that heparin and aSN(1–61) co-exist in the final fibrils. We conclude that heparin can induce the fibrillation of aSN(1–61), through binding to the N-terminal with an affinity that is higher in the truncated form of aSN. It does so by specifically modulating the structure of aSN via the formation of type I β-turn structures likely critical for triggering aSN fibrillation. |
format | Online Article Text |
id | pubmed-7464290 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74642902020-09-04 The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin Skaanning, Line K. Santoro, Angelo Skamris, Thomas Martinsen, Jacob Hertz D’Ursi, Anna Maria Bucciarelli, Saskia Vestergaard, Bente Bugge, Katrine Langkilde, Annette Eva Kragelund, Birthe B. Biomolecules Article The intrinsically disordered protein α-synuclein (aSN) is, in its fibrillated state, the main component of Lewy bodies—hallmarks of Parkinson’s disease. Additional Lewy body components include glycosaminoglycans, including heparan sulfate proteoglycans. In humans, heparan sulfate has, in an age-dependent manner, shown increased levels of sulfation. Heparin, a highly sulfated glycosaminoglycan, is a relevant mimic for mature heparan sulfate and has been shown to influence aSN fibrillation. Here, we decompose the underlying properties of the interaction between heparin and aSN and the effect of heparin on fibrillation. Via the isolation of the first 61 residues of aSN, which lacked intrinsic fibrillation propensity, fibrillation could be induced by heparin, and access to the initial steps in fibrillation was possible. Here, structural changes with shifts from disorder via type I β-turns to β-sheets were revealed, correlating with an increase in the aSN(1–61)/heparin molar ratio. Fluorescence microscopy revealed that heparin and aSN(1–61) co-exist in the final fibrils. We conclude that heparin can induce the fibrillation of aSN(1–61), through binding to the N-terminal with an affinity that is higher in the truncated form of aSN. It does so by specifically modulating the structure of aSN via the formation of type I β-turn structures likely critical for triggering aSN fibrillation. MDPI 2020-08-16 /pmc/articles/PMC7464290/ /pubmed/32824376 http://dx.doi.org/10.3390/biom10081192 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Skaanning, Line K. Santoro, Angelo Skamris, Thomas Martinsen, Jacob Hertz D’Ursi, Anna Maria Bucciarelli, Saskia Vestergaard, Bente Bugge, Katrine Langkilde, Annette Eva Kragelund, Birthe B. The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin |
title | The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin |
title_full | The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin |
title_fullStr | The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin |
title_full_unstemmed | The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin |
title_short | The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin |
title_sort | non-fibrillating n-terminal of α-synuclein binds and co-fibrillates with heparin |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464290/ https://www.ncbi.nlm.nih.gov/pubmed/32824376 http://dx.doi.org/10.3390/biom10081192 |
work_keys_str_mv | AT skaanninglinek thenonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin AT santoroangelo thenonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin AT skamristhomas thenonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin AT martinsenjacobhertz thenonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin AT dursiannamaria thenonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin AT bucciarellisaskia thenonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin AT vestergaardbente thenonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin AT buggekatrine thenonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin AT langkildeannetteeva thenonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin AT kragelundbirtheb thenonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin AT skaanninglinek nonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin AT santoroangelo nonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin AT skamristhomas nonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin AT martinsenjacobhertz nonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin AT dursiannamaria nonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin AT bucciarellisaskia nonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin AT vestergaardbente nonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin AT buggekatrine nonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin AT langkildeannetteeva nonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin AT kragelundbirtheb nonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin |